GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » RLS Global AB (OSTO:RLS) » Definitions » Debt-to-EBITDA

RLS Global AB (OSTO:RLS) Debt-to-EBITDA : 0.00 (As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is RLS Global AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

RLS Global AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was kr0.00 Mil. RLS Global AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was kr0.00 Mil. RLS Global AB's annualized EBITDA for the quarter that ended in Jun. 2023 was kr-28.49 Mil. RLS Global AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RLS Global AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:RLS's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.71
* Ranked among companies with meaningful Debt-to-EBITDA only.

RLS Global AB Debt-to-EBITDA Historical Data

The historical data trend for RLS Global AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RLS Global AB Debt-to-EBITDA Chart

RLS Global AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RLS Global AB Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 - - - -

Competitive Comparison of RLS Global AB's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, RLS Global AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RLS Global AB's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RLS Global AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RLS Global AB's Debt-to-EBITDA falls into.



RLS Global AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RLS Global AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -22.299
=0.00

RLS Global AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -28.492
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


RLS Global AB  (OSTO:RLS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


RLS Global AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RLS Global AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


RLS Global AB (OSTO:RLS) Business Description

Traded in Other Exchanges
N/A
Address
Neongatan 5, Mölndal, SWE, 431 53
RLS Global AB develops and sells biochemical products for the treatment of some of common diseases in wound and dental care.

RLS Global AB (OSTO:RLS) Headlines

No Headlines